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StatinsSolvent-free desymmetrisation of meso-dialdehyde 1 with chiral 1-phenylethan-1-ol, led to preparation
of 4-silyloxy-6-alkyloxytetrahydro-2H-pyran-2-one (+)-3a with a 96:4 dr Deprotected lactone (+)-19a
and the related racemic lactones 16a–18a present a lactone moiety resembling the natural substrate of
HMG-CoA reductase and their antifungal properties have been evaluated against the phytopathogenic
fungi Botrytis cinerea and Colletotrichum gloeosporioides. These compounds were selectively active against
B. cinerea, while inactive against C. gloeosporioides.
 2015 Elsevier Ltd. All rights reserved.1. Introduction
Botrytis cinerea is a fungal pathogen which affects a wide range
of cultivars.1 Variation in the attack modes, diversity of host and its
survival ability, are on the basis of the difficulties found on the con-
trol of this phytopathogen.2 Use of chemical control agents against
B. cinerea is hampered by the development of resistance3 to some
active principles, such as benzimidazoles.4,5 On the other hand,
there are public concerns on the safe use of chemical control
agents and their impact in the environment, which involves tighter
regulations on the use of new and established pesticides.6,7
Response to these problems involves a careful, coordinated use
of chemical control agents, like application of mixed chemical
fungicides spray progammes.8 Furthermore, there is considerable
interest in the development of compounds which are compatible
with integrated pest management practices; for instance these
compounds should be compatible with the use of plant defense
system activators such as acibenzolar, an analogue of salicylic
acid,9 and biological control.6
Interaction between B. cinerea and the host is considered to
involve the production of necrosis inducing factors that include
proteins, reactive oxygen species, cell wall degrading enzymes,peptidases, phytohormones and phytotoxic metabolites like botry-
dial and botcinic acid,10–12 which are considered to be virulence
factors (strain dependent).
Our research group has explored for some years a strategy of
selective control of Botrytis cinerea through interference with viru-
lence factors such as fungal toxins.13 Studies on the fungal toxins
from B. cinerea have shown their diverse biosynthetic origins.
Botrydial and related compounds originated from mevalonate
pathway through FPP and further cyclization.14–17 Botcinins18 orig-
inated through poliketide biosynthetic pathway.19,20 Gene silenc-
ing studies have shown that blockade of one toxin metabolic
pathway does not completely eliminate the pathogenicity of the
fungus, due to the metabolic switch to another fungal toxin
pathway.21,22
At the same time, genomic studies have been unraveling the
complex metabolic potential of this versatile phytopathogen,
showing that the genome of B. cinerea comprises 45 genes encod-
ing secondary metabolites key enzymes including 22 polyketide
synthases (PKSs), 8 non-ribosomal peptide synthetases (NRPSs), 5
PKS/NRPS, six sesquiterpene cyclases (STCs), three diterpene
cyclases (DTCs) and one dimethylallyl tryptophan synthase
(DMATS).23 As shown in the botrydial/botcinic acid switch, role
and expression conditions of the cryptic metabolites encoded by
the above mentioned genes may shed some light on the infection
mechanisms of the fungus.




3380 J. M. Botubol-Ares et al. / Bioorg. Med. Chem. 23 (2015) 3379–3387Much of our previous work has been focused on the develop-
ment of metabolic analogues to botrydial biosynthetic intermedi-
ates as a way to control the fungus.13 This has allowed the
preparation of sesquiterpene lead compounds as antifungal
agents.24 As shown by the genomic analysis, other terpenoids
may be involved in the infective stages of the development of
the fungus. Therefore, further work on the control of the fungus
through inhibition of toxin production requires the preparation
of compounds developed as selective inhibitors of the mevalonate
pathway at an earlier stage in the biosynthetic pathway of
sesquiterpenic toxins like botridial, so further studies could be
developed on non mutant specimens. Furthermore, inhibition of
mevalonate pathway should affect the production of constitutive
steroids like ergosterol. Therefore, such compounds would have
potential as antifungal agents, either on their own or in combina-
tion with other compounds.
Statins are a family of compounds that inhibit the formation of
mevalonate through of the inhibition of the 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase enzyme. Endo’s original
hypothesis25 for the development of HMG-CoA reductase selective
inhibitors considered that those inhibitors found from microbial
sources could be also applied to the inhibition of human HMG-
CoA reductase. This led to the discovery of compactin and develop-
ment of the statins, either from natural or synthetic sources,26
which find widespread use in treatment of high triglyceride
levels27 and hyperlipidemia in humans.28 As shown in recent find-
ings of the inhibitory action of statins such as simvastatin and ator-
vastatin on the growth of Aspergillus fumigatus and Candida fungi,29
where fungal growth is recovered once ergosterol is provided
exogenously, this reasoning may work in both ways. Moreover,
quite likely, not all fungal HMG-CoA reductases are expected to
have the same affinity for the above mentioned statins, and there-
fore they will not affect either fungal growth or sesquiterpenoid
production. An example is the lack of significative effect on fungal
growth of lovastatin when evaluated against B. cinerea.30
Therefore, the development of inhibitors of mevalonate path-
way with potential antifungal activity against B. cinerea requires
the preparation of novel lead compounds, related to known statins,
which could be further developed into agents for the control of the
fungus.
Statins show a common structural pattern, wherein a hydroxy-
lactone moiety, reminiscent of mevalonic acid, is connected to a
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Figure 1. General structural pattern of representative statins.more frequently X and Y can be CH2, like in compactin, simvastatin
or atorvastatin, or can be methyne groups like in cerivastatin.
Furthermore, there are examples of active compounds where X is
CH2 and Y is oxygen (Fig. 1).31 In addition, the stereochemistry of
the stereogenic centers involved is defined and must be taken into
account. To our knowledge there are no precedents for the prepa-
ration and evaluation of compounds with X = O.
As part of our strategy for the design of antifungal agents
against Botrytis and Colletotrichum species,13 we report the prepa-
ration of 6-alkyloxy-4-hydroxytetrahydro-2H-pyran-2-ones
(Fig. 1, X = O, Y = alkyl, A = aryl) which present a lactone moiety
resembling the natural substrate of HMG-CoA reductase and the
evaluation of the antifungal activities of selected substrates, either
enantiomerically pure or racemic. Enantiomerically pure com-
pounds are obtained via the desymmetrisation32 reaction of a suit-
able meso-dialdehyde33 precursor (1) with a chiral alcohol.34
2. Results and discussion
2.1. Optimization of desymmetrisation reaction
Enantioselective preparation of methyl 3-(tert-butyldimethylsi-
lyloxy)-5-oxopentanoates (methyl nor-mevaldate derivatives) has
been previously described in earlier reports from our research
group through desymmetrisation of the dialdehyde 1 with (+)-
(R)-1-phenylethan-1-ol (2) to afford chiral 6-arylalkyloxy-4-sily-
loxytetrahydro-2H-pyran-2-ones (+)-3a and (+)-3b in a 9:1 dr
(Scheme 1).34 The absolute stereochemistries of lactones (+)-3a
and (+)-3b were established unequivocally by a combination of
X-ray crystallographic analyses of the structurally related lactones
(+)-5a and ()-5c, NOE difference studies and chemical correlation
of lactones (+)-3a and (+)-5a with ()-(R) methyl 3-(tert-
butyldimethylsilyloxy)-5-oxopentanoate (6) and of lactones (+)-
3b and ()-5c with (+)-(S) methyl 3-(tert-butyldimethylsilyloxy)-
5-oxopentanoate (7) (Scheme 2).34 (1H NMR data for compounds
3a, 3b,34 5a and 5c in Table 3; 13C NMR data for compounds 3a,








































































































Scheme 3. Synthesis of the dialdehyde 1.
J. M. Botubol-Ares et al. / Bioorg. Med. Chem. 23 (2015) 3379–3387 3381The configuration observed for the compounds 3a and 5a
involves an axial distribution for the alkyloxy substituent on C-6
which would stabilize the configurations of the hemiacetal precur-
sor with the axial exocyclic C–O bond by the anomeric effect
instead of the equatorial disposition which is present in the lac-
tones 3b and 5c (Fig. 2). These conformations are consistent with
those observed in many related substituted d-lactones.35
Applicability of these lactones required improvements in the
number of steps needed for the preparation of the meso-precursor
and in the diastereoselectivity of the desymmetrisation reaction.
Dialdehyde 1, previously prepared in a 6-step synthetic
sequence,34 was improved using an abridged synthetic sequence
(Scheme 3) in 60% overall yield, starting from hepta-1,6-dien-4-
ol, which was subjected to protection with TBSCl, subsequent
reductive ozonolysis and dehydration of the hydrate 9.36
Efforts were then made to improve the yields and/or increase
the selectivity of the desymmetrisation reaction using enantiomer-
ically pure 1-phenylethanol, evaluating the influence of several
catalysts and reagents. A slight increase in the overall yield was
observed when a catalytic amount of p-toluenesulfonic acid, tin
(II) triflate or 1 equiv of N,N0-diisopropylethylamine (DIPEA) were
employed (Table 1, entries 3, 4 and 8), but unfortunately at the cost
of a decrease in the diastereoselectivity in the production of com-
pounds 3a and 3b. The addition of catalytic amounts of modified
cinchona alkaloids such (DHQD)2AQN and (DHQD)2PHAL37
(Table 1, entries 5 and 6) or Cr (III) Salen38 complexes (Table 1,
entry 7) neither increased the yields nor improved the selectivity
of the reaction.
Given the tendency of dialdehyde 1 to transform into its
hydrated form, and in order to avoid the use of dry THF, we decided
to evaluate the reaction under solvent-free conditions.39
Gratifyingly, treatment of the freshly reconstituted dialdehyde 1
with 2.9 equiv of (R)-1-phenylethanol and 4 Å molecular sieves at
room temperature under solvent-free conditions yielded lactone
3a in a 96:4 dr (92% de) (Table 2, entry 4),40 an improvement on
previously described conditions.34
2.2. Preparation of 6-arylalkyloxy-4-hydroxytetrahydro-2H-
pyran-2-ones for antifungal testing
A selection of simple achiral arylethanols, related to 1-pheny-
lethan-1-ol, with modifications in the aromatic ring, was chosen
in order to prepare a range of 6-arylalkyloxy-4-hydroxytetrahy-
dro-2H-pyran-2-one analogs of 3a, as compounds which present
a lactone moiety resembling the natural substrate of HMG-CoA
reductase, in order to evaluate their antifungal properties.
Thereby, dialdehyde 1 was treated, as described above, with alco-
hols 10–12 in the presence of 4 Å molecular sieves at room temper-
ature, except in the case of alcohol 11 where the reaction was
heated to 40 C. The crude lactols thus obtained were subsequently
oxidized with PCC to afford the lactones (±)-13a–15a (Scheme 4).
1H NMR spectroscopic data and coupling constants for H-3 and
H-5 signals in these tetrahydro-2H-pyran-2-ones were comparable





















Scheme 2. Chemical correlation of lactones (+)-3a and (+)-5a with compound ()-
(R)-6 and of lactones (+)-3b and ()-5c with (+)-(S)-7.to assign the structures and relative stereochemistries for these
compounds as (±)-(3R(S),5S(R))-6-(arylalkyloxy)-4-(tert-butyl-
dimethylsilyloxy)tetrahydro-2H-pyran-2-ones ((±)-13a–15a). (1H
NMR data for compounds 13a–15a in Table 3; 13C NMR data for
compounds 13a–15a in Table S3 of the SI). Removal of the TBS
group through treatment of compounds 13a–15a and 5a with the
TBAF/AcOH41 system afforded the corresponding 6-arylalkyloxy-4-
hydroxytetrahydro-2H-pyran-2-ones (±)-16a–18a and (+)-19a
required for the essays, in moderate to good yields (Scheme 4).
Treatment of compound 3b with the TBAF/AcOH41 system afforded
(4S,6S)-4-hydroxy-6-((R)-1-phenylethoxy)tetrahydro-2H-pyran-2-
one (19b) in a 72% yield.
Table 1
Desymmetrisation of dialdehyde 1 with either (R)-1-phenylethanol (2) or methyl (S)-
mandelate (4) using catalysts/reagentsa
Entry Alcohol Reagent Products (%) drb
1 2 — 3a (9), 3b (1) 90:1034
2 4 — 5a (9), 5c (6) 60:4034
3 2 p-TsOH (10 mol %) 3a (12), 3b (3) 80:20
4 2 Sn(OTf)2 (10 mol ) 3a (15), 3b (3) 83:17
5 2 (DHQD)2PHAL (10% mol)c 3a (9), 3b (1) 90:10
6 2 (DHQD)2AQN (10 mol %)d 3a (9), 3b (1) 90:10
7 2 (S,S) Cr(III) Salen (1 equiv)e 3a (8), 3b (2) 80:20
8 2 DIPEA (1 equiv)f 3a (17), 3b (8) 68:32
a Yields obtained after chromatographic purification.
b Diasteroisomer ratios: ratio normalized to 100% between both diasteroisomers.
c (DHQD)2PHAL = hydroquinidine 1,4-phthalazinediyl diether.
d (DHQD)2AQN = hydroquinidine (anthraquinone-1,4-diyl) diether.
e (S,S) Cr(III) Salen = (+)-(S,S)-N,N0-bis-(3,5-di-tert-butalicylidene)-(1,2-cyclohex-
anediamine) chromium (III) chloride.
f N,N0-Diisopropylethylamine.
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3382 J. M. Botubol-Ares et al. / Bioorg. Med. Chem. 23 (2015) 3379–3387Given that the structures of compounds (+)-19a and (+)-19b
could be established, respectively, as (4R,6S)-4-hydroxy-6-((R)-1-
phenylethoxy)tetrahydro-2H-pyran-2-one and (4S,6S)-4-hydroxy-
6-((R)-1-phenylethoxy)tetrahydro-2H-pyran-2-one by chemical
correlation, the structures and relative stereochemistries of com-
pounds (±)-16a–18a were assigned by comparison of spectroscopic
data for deprotected lactone (+)-19a; this, in turn, confirmed the
structure and relative stereochemistries assigned for parent com-
pounds (±)-13a–15a. (1H NMR data for compounds 16a–18a, 19a
and 19b in Table 4; 13C NMR data for compounds 16a–18a, 19a
and 19b in Table S4 of the SI.)
2.3. Antifungal activity
The antifungal properties of compounds (±)-16a–18a and (+)-
19a, were determined against the growth of the phytopathogenic
fungi Botrytis cinerea and Colletotrichum gloeosporioides at a con-
centration of 200 ppm using the poisoned food technique42 (see
fungal growth inhibition graphics, Figs. 3 and 4). The commercial
fungicide Euparen (dichlofluanid) was used as a standard for
comparison in this test. Several levels of inhibition were observed
(Figs. 3 and 4). Compounds (±)-16a–18a and (+)-19a showed a sub-
stantial activity against B. cinerea (63–72% fungal growth inhibition
after 6 d, see Supporting information, Table S1). However, very lit-
tle inhibition was observed against C. gloeosporioides. (Fig. 4, see
also Supporting information, Table S2).
3. Conclusions
This selective inhibition of the growth of B. cinerea is of great
interest as it opens the way to the design of selective fungicides
against phytopathogenic fungi of the genus Botrytis and a potential
integrated control of the fungus by combining selective fungicides
and antagonistic fungi such as Trichoderma species,43 whichTable 2
Optimization of solvent-free desymmetrisation of dialdehyde 1 with (R)-1-pheny-
lethanol (2)a
Entry 2 (equiv) 3aa (%) 3ba (%) drb dec (%)
1 9.5 5 1.2 80:20 60
2 5.0 7.5 1.4 84:16 68
3 3.5 7.1 0.9 89:11 78
4 2.9 12.3 0.6 96:4 92
a Yields obtained after chromatographic purification.
b Diasteroisomer ratios: ratio normalized to 100% between both diasteroisomers.
c de% = 100 (3a%3b%)/(3a% + 3b%).potentially would not be affected by the fungicides aimed at
Botrytis.44,45 The mode of action of these compounds may be
related with the inhibition of the biosynthesis of terpenes, such
as the sesquiterpene phytotoxin botrydial,13 and this will be fur-
ther explored. Interestingly, no terpenes have been reported from
Colletotrichum spp., except for Colletotrichum nicotiniae.46
4. Experimental section
4.1. General
Unless otherwise noted, materials and reagents were obtained
from commercial suppliers and were used without further purifi-
cation. Dichloromethane was freshly distilled from CaH2 and
tetrahydrofuran was dried over sodium and benzophenone and
freshly distilled before use. Air- and moisture-sensitive reactions
were performed under an argon atmosphere. Melting points were
measured with a Reichert-Jung Kofler block and are uncorrected.
Optical rotations were determined on a Perkin-Elmer 341
polarimeter. IR spectra were recorded on a Perkin-Elmer
Spectrum BX FT-IR spectrophotometer. 1H and 13C NMR spectra
were obtained on Varian Gemini 300, Varian INOVA 400 and
Agilent 500 MHz NMR spectrometers using tetramethylsilane as
an internal reference. NMR assignments were made by a combina-
tion of 1D and 2D techniques and by comparison with assignments
available in the literature for previously described compounds,
where appropriate. Mass spectra were recorded on a Finnigan
Voyager spectrometer at 70 eV. High resolution mass spectra were
recorded on a Micromass Autospec spectrometer at 70 eV or in a
Waters Synapt G2 QTOF mass spectrometer in positive ion electro-

















Scheme 4. Preparation of deprotected lactones and (±)-16a–18a, (+)-19a and (+)-
19b.
Table 3
1H NMR spectroscopic data for 3a, 5a, 3b, 5c, (±)-13a, (±)-14a, (±)-15a
Position 3a34 5a 3b34 5c (±)-13a (±)-14a (±)-15a
dH (mult, J in Hz)a dH (mult, J in Hz)b dH (mult, J in Hz)a dH (mult, J in Hz)c dH (mult, J in Hz)a dH (mult, J in Hz)a dH (mult, J in Hz)a
3 a: 2.47, dd, (17.2, 5.6)
b: 2.76, dd, (17.2, 4.8)
a: 2.50, dd, (17.2, 5.6)
b: 2.85, ddd, (17.2, 4.8, 1.2)
a: 2.51, dd, (16.8, 9.2)
b: 2.69 ddd, (16.8, 5.4, 1.8)
a: 2.50, dd, (17.3, 4.8)
b: 2.71 dd, (17.3, 4.8)
a: 2.52, dd, (17.4, 5.6)
b: 2.78 dd, (17.4, 4.8)
a: 2.51, dd, (17.4, 5.6)
b: 2.78 dd, (17.4, 4.8)
a: 2.51, dd, (17.2, 5.4)
b: 2.76 dd, (17.2, 4.6)
4 4.33, m 4.44, m 3.98, tt (9.2, 5.4) 4.38, quint (4.8) 4.36, m 4.36, m 4.35, m
5 a: 1.94, ddd (13.8,
5.6, 3.6)
b: 1.85, ddd (13.8,
6.8, 3.6)
a: 2.13, dddd (14.0, 4.8, 3.8, 1.2)
b: 1.95, ddd (14.0, 6.8, 3.8)
a 1.82, ddd (14.0, 9.2, 7.7)
b: 2.22, dddd (14.0, 5.4, 4.4, 1.8)
a,b: 2.17, t (4.8) a, b: 2.05–1.95 a, b: 2.06–1.95 a, b: 2.00, t (4.4)
6 5.25, dd (5.6, 3.6) 5.37, dd (4.8, 3.8) 5.04, dd (7.7, 4.4) 5.64, t (4.8) 5.50, dd (5.2, 4.0) 5.51, dd (5.2, 4.0) 5.48, t (4.4)
Si(CH3)(CH3) *0.02, s *0.04, s *0.03, s *0.09, s *0.06, s *0.06, s *0.05, s
Si(CH3)(CH3) *0.03, s *0.00, s *0.03, s *0.08, s *0.04, s *0.05, s *0.04, s
SiC(CH3)3 0.76, s 0.79, s 0.86, s 0.88, s 0.84, s 0.86, s 0.84, s
20 7.36–7.28 7.44–7.36 7.38–7.28 7.40–7.35 7.37–7.29 — 7.32–7.26
30 7.36–7.28 7.44–7.36 7.38–7.28 7.40–7.35 7.37–7.29 7.19–7.17, m 7.05–7.01
40 7.36–7.28 7.44–7.36 7.38–7.28 7.40–7.35 7.37–7.29 7.24–7.20 –
50 7.36–7.28 7.44–7.36 7.38–7.28 7.40–7.35 7.37–7.29 7.24–7.20 7.05–7.01
60 7.36–7.28 7.44–7.36 7.38–7.28 7.40–7.35 7.37–7.29 7.31–7.28, m 7.32–7.26
o-CH3PhCH2O — — — — 2.32, s —
ArCH(H)O — — — 4.93, d (11.8) 4.97, d (11.8) 4.89, d (11.8)
ArCH(H)O — — — 4.63, d (11.8) 4.61, d (11.8) 4.60, d (11.8)
CH3OCO — 3.69, s — 3.72, s — — —
ArCH(CH3)O 1.46, d (6.6) — 1.47, d (6.6) — — —
ArCH(R1)O 4.99, q (6.6) 5.32, s 5.01, q (6.6) 5.48, s — — —
a Acquired in CDCl3 (400 MHz).
b Acquired in CDCl3 (300 MHz).














1H NMR spectroscopic data for (±)-16a–18a, 19a and 19b
Position (±)-16a (±)-17a (±)-18a 19a 19b
dH (mult, J in Hz)a dH (mult, J in Hz)a dH (mult, J in Hz)a dH (mult, J in Hz)a dH (mult, J in Hz)a
3 a: 2.54, ddd, (17.6, 6.4, 0.8)
b: 2.92, ddd, (17.6, 5.2, 1.2)
a: 2.51, ddd, (17.4, 6.4, 0.8)
b: 2.87, ddd, (17.4, 5.2, 0.8)
a: 2.55, ddd, (17.6, 6.2, 0.8)
b: 2.91, ddd, (17.6, 5.2, 0.8)
a: 2.51, ddd, (17.4, 6.4, 0.8)
b: 2.94, ddd, (17.4, 5.6, 1.2)
a, b: 2.84
4 4.46, m 4.40, m 4.45, m 4.48, m 4.23, dtt (8.8, 5.2,
4.0)
5 a: 2.02, dddd (13.8, 7.6, 4.0,
0.8)
b: 2.18, ddt (13.8, 4.0, 1.2)
a: 1.98, dddd (14.0, 7.6, 4.0,
0.8)
b: 2.12, ddt (14.0, 4.0, 0.8)
a: 2.03, dddd (13.6, 7.6, 4.2,
0.8)
b: 2.16, ddt (13.6, 4.2, 1.2)
a: 1.89, dddd (14.0, 8.0, 4.0,
0.8)
b: 2.11, ddt (14.0, 4.0, 1.2)
a, b: 2.09
6 5.53, t (4.0) 5.50, t (4.0) 5.52, t (4.2) 5.26, t (4.0) 5.25, t (4.0)
20 7.37–7.30 — 7.31–7.27 7.37–7.27 7.37–7.35
30 7.37–7.30 7.16–7.14 7.06–7.01 7.37–7.27 7.33–7.30
40 7.37–7.30 7.22–7.17 — 7.37–7.27 7.33–7.30
50 7.37–7.30 7.22–7.17 7.06–7.01 7.37–7.27 7.33–7.30
60 7.37–7.30 7.26–7.24 7.31–7.27 7.37–7.27 7.37–7.35
o-CH3PhCH2O — 2.28, s — — —
ArCH(H)O 4.90, d (11.8) 4.91, d (11.6) 4.85, d (11.6) — —
ArCH(H)O 4.62, d (11.8) 4.55, d (11.6) 4.57, d (11.6) — —
ArCH(CH3)O — — — 1.43, d (6.4) 1.50, d (6.6)
ArCH(CH3)O — — — 4.96, q (6.4) 5.04, q (6.6)
OH — — — — 3.25, d (8.8)


























Figure 3. Comparison of fungal growth inhibition (B. cinerea) among compounds


























Figure 4. Comparison of fungal growth inhibition (C. gloeosporioides) among 16a–
19a (200 ppm dose; 16a (0.90103 M), 17a, 19a (0.85103 M) and 18a
(0.83103 M).
3384 J. M. Botubol-Ares et al. / Bioorg. Med. Chem. 23 (2015) 3379–3387Hitachi/Merck L-6270 apparatus equipped with a UV–VIS detector
(L 4250) and a differential refractometer detector (RI-71). TLC was
performed on Merck Kiesegel 60 F254, 0.2 mm thick. Silica gel
(Merck) was used for column chromatography. Purification by
HPLC was performed using a Si gel column (LiChrospher Si 60,
10 lm, 1 cm wide, 25 cm long).
4.2. Microorganism and antifungal assays
The culture of Botrytis cinerea strain UCA 992 employed in this
work was isolated from Domecq vineyard grapes, Jerez de la
Frontera, Cádiz, Spain. This culture of B. cinerea has been deposited
at the Mycological Herbarium Collection (UCA), Facultad de
Ciencias, Universidad de Cádiz. The culture of Colletotrichum
gloeosporioides utilized, C. gloeosporioides CECT 20122, wasobtained from the Colección Española de Cultivos Tipo Collection
Depository. The growth medium was poured into 9 cm diameter
sterile plastic petri dishes, and a 5 mm diameter mycelial disk of
B. cinerea or C. gloeosporioides cut from an actively growing culture
was placed in the center of the plate. Antifungal bioassays were
performed by measuring radial growth on agar medium for B.
cinerea and potato-dextrose-agar (PDA) for C. gloeosporioides in
the presence of test compounds. Test compounds were dissolved
in EtOH to a final compound concentration in the culture medium
of 200 mg L1. The final EtOH concentration was identical in both
the control and treated cultures. Radial growth was measured for
five days for C. gloeosporioides and for 6 days for B. cinerea; exper-
iments were carried out at 25 C, in triplicate. The percentage
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the following formula.47
I ð%Þ ¼ ðC  TÞðC  T0Þ
 100
I = Inhibition rate
C = Diameter of control colony
T = Diameter of treated colony
T0 = Initial diameter of treated colony
4.3. Procedures
4.3.1. Preparation of 4-(tert-butyldimethylsilyloxy)hepta-1,6-
diene (8)
A solution of tert-butyldimethylsilane chloride (TBSCl) (4.2 g,
26.8 mmol) in dry THF (7 mL) was added to a stirred solution of
imidazole (8.6 g, 142.9 mmol) and hepta-1,6-dien-4-ol (2.0 g,
17.86 mmol) in dry THF (25 mL) at 0 C under an argon atmo-
sphere. The mixture was allowed to warm to room temperature
and when TLC analysis indicated completion of reaction (16 h)
diethyl ether was added (60 mL). The organic layer was washed
three times with brine (40 mL), dried over anhydrous sodium sul-
fate and filtered. Evaporation of the solvent gave a residue that was
purified by silica gel column chromatography (petroleum
ether/EtOAc, 90:10), to yield compound 8 (3.8 g, 95%).
Spectroscopic data for compound 9 were identical to those
described in the literature.48
4.3.2. Preparation of 3-(tert-butyldimethylsilyloxy)pentanedial
(1)
Ozone was bubbled through a stirred solution of 4-(tert-
butyldimethylsilyloxy)hepta-1,6-diene (8) (3.2 g, 14.37 mmol) in
CH2Cl2 (30 mL) under an argon atmosphere at 78C until a per-
manent blue coloration was obtained (25 min). Oxygen was subse-
quently bubbled through the solution (5 min) and then dimethyl
sulfide was slowly added (18 mL), which led to disappearance of
the blue coloration, the reaction was allowed to warm to room
temperature and stirred for further 48 h. The organic layer was
washed three times with brine (40 mL), dried over anhydrous
sodium sulfate and filtered. Evaporation of the solvent under
reduced pressure gave a residue (3.3 g) which was refluxed in
dry THF (150 mL) in the presence of 4 Å molecular sieves (11.3 g)
for 16 h. Then, the reaction was allowed to cool to room tempera-
ture, filtered through a pad of Celite and the solvent evaporated
under reduced pressure to yield 3-(tert-butyldimethylsily-
loxy)pentanedial (1) (2115 mg, 64%) as a colorless oil, which was
utilized immediately without chromatographic purification.
Spectroscopic data for compound 1 were identical to those
described in the literature.36b4.3.3. General procedure for the preparation of 6-alkyloxy-4-
(tert-butyldimethylsilyloxy)tetrahydro-2H-pyran-2-ones
(3a and b, 5a and 5c): Desymmetrisation of 3-(tert-butyldime-
thylsilyloxy)pentanedial (1) under reflux followed by THF/PCC
oxidation
Either (R)-1-phenylethanol (2.7 mmol) or (S)-methyl mandelate
(2.7 mmol) were added to a suspension of the reagents detailed in
Table 1, dialdehyde 1 (2.5 mmol) and 4 Å powdered molecular
sieves (2.5 g) in dry THF (10 mL). The slurry was refluxed for
24 h, filtered through Celite and the THF was removed under
reduced pressure to yield an oil, which was dissolved in DCM
(12 mL) and then added dropwise to a suspension of PCC
(3.2 mmol) and powdered 4 Å molecular sieves (1.4 g) in DCM
(15 mL) at room temperature. The reaction was stirred vigorouslyat room temperature for 18 h, diethyl ether was then added and
the mixture was stirred for a further 1 h. The suspension was fil-
tered through a pad of silica gel, and washed through with further
ether. The ether was removed under reduced pressure to give the
crude mixture of tetrahydro-2H-pyran-2-ones. Further purification
by column chromatography (petroleum ether/Et2O 90:10) yielded
the corresponding tetrahydro-2H-pyran-2-ones 3a, 3b (from (R)-
1-phenylethanol) or 5a and 5c (from (S)-methyl mandelate) in
the yields and ratios shown in Table 1.
4.3.3.1. (4R,6S)-4-((tert-butyldimethylsilyl)oxy)-6-((R)-1-pheny-
lethoxy)tetrahydro-2H-pyran-2-one (3a)34. Colorless oil;
HPLC tR = 41 min (Petroleum ether: ethyl acetate 93:7;
flow = 3.0 mL/min); [a]D20 +157 (c 1.0, CHCl3); IR (film) tmax
2927, 2857, 1752, 1560, 1229, 1024 cm1; 1H NMR (CDCl3,
400 MHz) (see Table 3); 13C NMR (CDCl3, 100 MHz) (see Table S3
of the SI); HRESIMS(+): m/z 373.1812 [M+Na]+ (calcd for
C19H30O4NaSi, 373.1811); m/z 229.1262 [M+H-C8H9OH]+(calcd for
C11H21O5Si, 229.1260).
4.3.3.2. 4S,6S)-4-((tert-butyldimethylsilyl)oxy)-6-((R)-1-pheny-
lethoxy)tetrahydro-2H-pyran-2-one (3b)34. Colorless oil;
HPLC tR = 33 min (Petroleum ether: ethyl acetate 93:7;
flow = 3.0 mL/min); [a]D20 +144 (c 0.4, CHCl3); IR (film) tmax
2927, 2857, 1752, 1560, 1229, 1024 cm-1; 1H NMR (CDCl3,
400 MHz) (see Table 3); 13C NMR (CDCl3, 100 MHz) (see Table S3
of the SI); HRESIMS(+): m/z 373.1811 [M+Na]+ (calcd for




Yellow solid, mp. 99–101 C; HPLC tR = 24 min (Petroleum ether:
ethyl acetate 88:12; flow = 3.5 mL/min); [a]D20 +153 (c 0.9,
CHCl3); IR (film) tmax 2954, 2858, 1757, 1559, 1211, 1105 cm1;
1H NMR (CDCl3, 300 MHz) (see Table 3); 13C NMR (CDCl3,
75 MHz) (see Table S3 of the SI); HRESIMS(+): m/z 417.1709
[M+Na]+ (calcd for C20H30O6NaSi, 417.1705); m/z 263.0917 [M+H-
C6H15SiOH]+ (calcd for C14H15O5, 263.0919).
4.3.3.4. (S)-methyl 2-(((2R,4S)-4-((tert-butyldimethylsilyl)oxy)-
6-oxotetrahydro-2H-pyran-2-yl)oxy)-2-phenylacetate (5c).
Yellow solid, m.p. 82–84 C; HPLC tR = 50 min (Petroleum ether:
ethyl acetate 93:7; flow = 3.5 mL/min); [a]D20 13 (c 0.16,
CHCl3); IR (film) tmax 2954, 2857, 1754, 1559, 1211, 1106 cm1;
1H NMR (CDCl3, 500 MHz) (see Table 3); 13C NMR (CDCl3,
125 MHz) (see Table S3 of the SI); HRESIMS(+): m/z 417.1705
[M+Na]+ (calcd for C20H30O6NaSi, 417.1709); m/z 263.0923 [M+H-
C6H15SiOH]+ (calcd for C14H15O5, 263.0919).
4.3.4. General procedure for the preparation of 6-alkyloxy-4-
(tert-butyldimethylsilyloxy)tetrahydro-2H-pyran-2-ones
(3a, 13a–15a). Desymmetrisation of 3-(tert-butyldime-
thylsilyloxy)pentanedial (1) under solvent-free conditions
followed by PCC oxidation
The requisite alcohol (See Table 2 and Scheme 4) (2.9 mmol)
was added to a mixture of 3-(tert-butyldimethylsilyloxy)pentane-
dial (1) (1 mmol) and 4 Å molecular sieves (0.5 g for each mmol
of 1) under an argon atmosphere and the mixture stirred for
24 h. The slurry was dissolved in dichloromethane (20 mL) and
added dropwise to a suspension of PCC (3.5 mmol) and powdered
molecular sieves 4 Å (twice the weight of the alcohol) in dichloro-
methane (70 mL) at room temperature. The reaction was stirred
vigorously for 18 h, diethyl ether was then added (200 mL) and
the mixture was stirred for a further 1 h. The suspension was fil-
tered through a pad of silica gel and washed through with a further
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pressure to give the crude mixture of tetrahydro-2H-pyran-2-ones
which was purified by column chromatography (petroleum
ether/Et2O, 90:10), to yield the corresponding tetrahydro-2H-
pyran-2-ones in the ratios and yields shown below and in
Table 2 and Scheme 4.
4.3.4.1. (±)-(4R(S),6S(R))-6-(benzyloxy)-4-((tert-butyldimethylsi-
lyl)oxy)tetrahydro-2H-pyran-2-one ((±)-13a). (57.1 mg,
17%) Colorless oil; IR (film) tmax 2928, 2856, 1752, 1673, 1594,
1252, 1024 cm1; 1H NMR (CDCl3, 400 MHz) (see Table 3); 13C
NMR (CDCl3, 100 MHz) (see Table S3 of the SI); HRMS (CI+): m/z
279.1054 [M-C(CH3)3]+ (calcd for C14H19O4Si, 279.1053).
4.3.4.2. (±)-(4R(S),6S(R))-4-((tert-butyldimethylsilyl)oxy)-6-((2-
methylbenzyl)oxy)tetrahydro-2H-pyran-2-one ((±)-14a).
(52.5 mg, 15%) Colorless oil; IR (film) tmax 2931, 2855, 1752,
1673, 1594, 1249, 1011 cm1; 1H NMR (CDCl3, 400 MHz) (see
Table 3); 13C NMR (CDCl3, 100 MHz) (see Table S3 of the SI);




(56.6 mg, 16%) Colorless oil; IR (film) tmax 2928, 2854, 1751,
1673, 1595, 1223, 1011 cm1; 1H NMR (CDCl3, 400 MHz) (see
Table 3); 13C NMR (CDCl3, 100 MHz) (see Table S3 of the SI);
HRMS (ESI-QTOF): m/z 377.1546 [M+Na]+ (calcd for
C18H27O4FNaSi, 377.1560).
4.3.5. General procedure for the preparation of 5-arylalkyloxy-
3-(hydroxy)pentane-5-lactones (16a–19a). Deprotection with
TBAF/AcOH41
1.0 M tetrabutylammonium fluoride (TBAF) (6 mmol) in THF
was added dropwise to a solution of the corresponding lactones
3a and (±)-13a–15a (1 mmol) and acetic acid (5 mmol) in dry
THF (6 mL) under an argon atmosphere at room temperature.
The reaction was stirred for 16 h and brine (10 mL) was then
added. The aqueous phase was extracted with ethyl acetate
(3  20 mL), dried over anhydrous sodium sulfate and filtered.
Evaporation of the solvent gave a crude product that was purified
by silica gel column chromatography (petroleum ether/EtOAc,
80:20), to afford the corresponding deprotected tetrahydro-2H-
pyran-2-ones (±)-16a–18a and 19a.
4.3.5.1. (±)-(4R(S),6S(R))-6-(benzyloxy)-4-hydroxytetrahydro-
2H-pyran-2-one ((±)-16a). (135.5 mg, 61%) Colorless oil; IR
(film) tmax 3417, 2940, 2850, 1732, 1681, 1238, 1020 cm1; 1H
NMR (CDCl3, 400 MHz) (see Table 4); 13C NMR (CDCl3, 100 MHz)
(see Table S4 of the SI); HRMS (CI+): m/z 223.0967 [M+H]+ (calcd
for C12H15O4 223.0970).
4.3.5.2. (±)-(4R(S),6S(R))-4-hydroxy-6-((2-methylbenzyl)oxy)te-
trahydro-2H-pyran-2-one ((±)-17a). (134.6 mg, 57%)
Colorless oil; IR (film) tmax 3398, 2945, 2879, 1727, 1570, 1224,
1019 cm1; 1H NMR (CDCl3, 400 MHz) (see Table 4); 13C NMR
(CDCl3, 100 MHz) (see Table S4 of the SI); HRMS (CI+): m/z
237.1133 [M+H]+ (calcd for C13H17O4, 237.1127).
4.3.5.3. (±)-(4R(S),6S(R))-6-((4-fluorobenzyl)oxy)-4-hydroxyte-
trahydro-2H-pyran-2-one ((±)-18a). (177.6 mg, 74%)
Colouless oil; 74% yield; IR (film) tmax 3417, 2938, 2854, 1732,
1604, 1512, 1223, 1023 cm1; 1H NMR (CDCl3, 400 MHz) (see
Table 4); 13C NMR (CDCl3, 100 MHz) (see Table S4 of the SI);
HRMS (CI+): m/z 240.0805 [M]+ (calcd for C12H13FO4, 240.0798).4.3.5.4. (4R,6S)-4-hydroxy-6-((R)-1-phenylethoxy)tetrahydro-
2H-pyran-2-one (19a). (170 mg, 72%) Colorless oil; HPLC
tR = 38 min (Petroleum ether: ethyl acetate 60:40; flow = 3.5
mL/min); [a]D20 +215.0 (c 0.5, CHCl3); IR (film) tmax 3398, 2927,
2857, 1752, 1560, 1229, 1024 cm1; 1H NMR (CDCl3, 400 MHz)
(see Table 4); 13C NMR (CDCl3, 100 MHz) (see Table S4 of the SI);
HRMS (CI+): m/z 221.0818 [M-CH3]+ (calcd for C12H13O4, 221.0814).
4.3.6. Preparation of (4S,6S)-4-hydroxy-6-((R)-1-phenylethoxy)-
tetrahydro-2H-pyran-2-one (19b)41
1.0 M tetrabutylammonium fluoride (TBAF) (0.6 mmol) in THF
was added dropwise to a solution of the corresponding tetrahy-
dro-2H-pyran-2-one 3b (0.05 mmol) and acetic acid (0.5 mmol)
in dry THF (0.6 mL) under an argon atmosphere at room tempera-
ture. The reaction was stirred for 16 h and brine (10 mL) was then
added. The aqueous phase was extracted with ethyl acetate
(3  20 mL), dried over anhydrous sodium sulfate and filtered.
Evaporation of the solvent gave a crude product that was purified
by silica gel column chromatography (petroleum ether/EtOAc,
80:20), to afford the corresponding deprotected tetrahydro-2H-
pyran-2-one 19b (8.5 mg, 72%) as a colorless oil; HPLC
tR = 47 min (Petroleum ether: ethyl acetate 60:40;
flow = 3.5 mL/min); [a]D20 +130.0 (c 0.1, CHCl3); IR (film) tmax
3412, 2927, 2857, 1752, 1560, 1229, 1024 cm1; 1H NMR (CDCl3,
400 MHz) (see Table 4); 13C NMR (CDCl3, 100 MHz) (see Table S4
of the SI); HRMS (CI+): m/z 221.0817 [M-CH3]+ (calcd for
C12H13O4, 221.0814).
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